Content matching 'bone marrow'
The Netherlands-based cell therapy company Kiadis Pharma BV is planning an initial public offering (IPO) of its shares on the Euronext stock exchanges in Amsterdam and Brussels to finance the clinical development of a cell therapy that helps reconstitute the immune system after a bone marrow transplant.
London-based Cell Medica Ltd has raised £50 million from institutional investors to support development of its lead oncology product, CMD-003, for the treatment of patients with advanced lymphomas associated with the Epstein Barr virus.
Noninvasive intranasal stem cells bypass the blood-brain barrier to target the brain to treat Parkinson's disease, stroke, MS, brain tumors, cerebral ischemia, Alzheimer's and other CNS disorders.
Regenerative medicine and therapeutic cell treatment of disorders of the brain and spinal cord are hindered by the blood-brain barrier. Invasive implantation of therapeutic cells in the brain, including stem cells and immune cells, is both risky and impractical. Noninvasive intranasal cell delivery to the CNS provides a solution to this problem.
Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease
Cell therapy weekly: FDA indicates more guidance is to come on cell therapy manufacture